New flu vaccine with booster additive enters human trials
NCT ID NCT06824519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new seasonal flu vaccine that includes an adjuvant (ZFA02) to potentially boost the immune response. The trial involves 620 adults aged 18 and older, split into low-dose and high-dose groups, with some receiving a placebo. Researchers will monitor side effects and measure antibody levels to see how well the vaccine works against four flu strains.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Influenza vaccine (split virion, inactivated, quadrivalent) with ZFA02 adjuvant
What this could lead to
If successful, this could lead to a more effective seasonal flu vaccine that provides broader protection against multiple flu strains.
What could go wrong
This is an early-phase trial (phase 1/2) with only 620 participants, so the vaccine may not prove safe or effective in larger populations. Side effects like injection-site reactions or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei Province Centers for Disease Control and Prevention
RECRUITINGShijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••